Antibiotic prophylaxis against infective endocarditis is not recommended routinely[1]: for people undergoing dental procedures for people undergoing non-dental procedures at the following sites[2]: upper and lower gastrointestinal tract genitourinary tract; this includes urological, gynaecological and obstetric procedures, and childbirth upper and lower respiratory tract; this includes ear, nose and throat procedures and bronchoscopy. Do not do recommendation December 2016
Alirocumab is not recommended for treating non-familial hypercholesterolaemia or mixed dyslipidaemia in adults without a history of cardiovascular disease. Do not do recommendation December 2016
Do not offer nicotinic acid (niacin) for the prevention of CVD to any of the following: people who are being treated for primary prevention, people who are being treated for secondary prevention, people with CKD, people with type 1 diabetes, people with type 2 diabetes. Do not do recommendation December 2016
Children with bronchiolitis are not prescribed antibiotics to treat the infection. Do not do recommendation December 2016
A fasting sample is not required when taking samples before starting lipid modification therapy for the primary prevention of CVD. Take at least 1 lipid sample to measure a full lipid profile. Do not do recommendation December 2016
Angiotensin-converting enzyme (ACE) inhibitors should not be used in people with FH who are being treated with LDL apheresis. Instead, ACE inhibitors should be substituted with angiotensin-receptor blocking agents. Do not do recommendation December 2016
Chlorhexidine mouthwash should not be offered as prophylaxis against infective endocarditis to people at risk of infective endocarditis undergoing dental procedures. [2015] Do not do recommendation December 2016
Do not delay statin treatment in secondary prevention to manage modifiable risk factors. Do not do recommendation December 2016
Do not advise any of the following to take plant stanols or sterols for the prevention of CVD: people who are being treated for primary prevention, people who are being treated for secondary prevention, people with CKD, people with type 1 diabetes, people with type 2 diabetes. Do not do recommendation December 2016
Coronary heart disease risk estimation tools such as those based on the Framingham algorithm should not be used because people with FH are already at a high risk of premature coronary heart disease. Do not do recommendation December 2016